MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developing and commercializing ...

On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.6 which represents a decrease of $-0.10 or -1.49% from the prior close of $6.7. The stock opened at $6.7 and touched a low of ...

MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.66 which represents a slight increase of $0.10 or 1.52% from the prior close of $6.56. The stock opened at $6.61 and touched a low ...

MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for MannKind in a research report issued on Monday, September 9th.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative ...

Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against the other 52-week high stocks. The start of the US Federal Reserve cutting cycle ushers a ...